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Abstract
Background: With recent advancements in molecular techniques, the opportunities to gather whole genome
information have increased, even in degraded samples such as FFPE tissues. As a result, a broader view of the
genomic landscape of solid tumors may be explored. Whole genome copy number and loss of heterozygosity
patterns can advance our understanding of mechanisms and complexity of various tumors.
Results: Genome-wide alterations involving copy number changes and loss of heterozygosity were identified in 17
glioma samples with positive FISH results for 1p19q co-deletions (n = 9) or EGFR amplification (n = 8). Gliomas positive
for 1p19q co-deletions did not have other frequently recurrent genomic alterations. Additional copy-number
alterations were observed in individual cases, and consisted primarily of large-scale changes, including gains or losses
of entire chromosomes. The genomic architecture of EGFR amplified gliomas was much more complex, with a high
number of gains and losses across the genome. Recurrent alterations in EGFR amplified gliomas were both focal, such
as CDKN2A homozygous deletions, and large, such as chromosome 10 loss.
Conclusions: Microarray enabled a broader picture of the genomic alterations occurring in glioma cases. Gliomas with
1p19q co-deletion had a relatively quiet genome, apart from the selected co-deletion. Additional alterations in isolated
cases, involved primarily larger aberrations. On the other hand, EGFR amplified cases tended to be more complex and
have specific abnormalities associated with the EGFR amplification. Furthermore, 1p19q co-deletions and EGFR
amplification associated copy number changes appeared to often be mutually exclusive.
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Background
Single nucleotide polymorphism (SNP) arrays allow for a
whole genome view of complex copy number changes
(CNCs) and loss of heterozygosity (LOH), Recent micro-
array developments have incorporated molecular in-
version probe (MIP) technology, which requires a
relatively small molecular footprint (~40 bp) and is ad-
vantageous for assessing highly cross-linked and de-
graded DNA samples obtained from formalin-fixed,
paraffin-embedded (FFPE) tissues [1, 2]. This ability to
optimally assess copy number changes in FFPE tissue
is significant to studying genomic alterations in solid
tumors because solid tumors have traditionally been
characterized through their histology and through
FFPE tissue FISH. As a result, FFPE-preserved solid
tumor samples have been archived for decades, await-
ing improved technologies to better analyze them. MIP
arrays, therefore, provide opportunities to characterize
genomic profiles from archived FFPE samples that are
already available for such studies.
This study focused on assessing the genomic signa-
tures of gliomas–brain tumors derived from the glial
cells. Gliomas are the most common form of primary
brain tumors comprising approximately 30 % of all brain
tumors. More importantly, about 80 % of all malignant
brain tumors are gliomas [3]. The World Health
Organization (WHO) has classified gliomas from I-IV
based on their degree of aggressiveness, with WHO class
I being relatively benign and WHO class IV as the most
aggressive gliomal tumors [4]. The objective of this study
was to investigate the genomic changes that occur in gli-
omas. We performed microarray analysis on 2 types of
glial tumors to identify and compare the respective gen-
omic landscapes.
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Results and discussion
The two categories of gliomas analyzed in this study
were initially identified by FISH testing and subsequently
assessed for CNCs using the OncoScan® array (Affyme-
trix, Santa Clara, CA). Global CNCs were analyzed to
identify consistent patterns across each cohort. The first
group consisted of nine oliogodendriolglial tumors that
had 1p19q co-deletions identified by FISH analysis. The
second group contained 8 glioblastomas (GBM), WHO
class IV, initially characterized by EGFR amplification,
also identified by FISH.
1p19q Co-deleted
Microarray results confirmed the 1p19q co-deletions.
One strength of array technology is the broader coverage
obtained in the assay. Significantly, FISH probes yield
very focal results, identifying only the 200–700 kb region
where the probe hybridizes. Array results show deletions
of the entire 1p and 19q arms in all 9 samples (Fig. 1a).
Typically, 1p19q co-deletions are consistent with a favor-
able prognosis, whereas partial 1p deletions are indica-
tive of a poor prognosis [5]. Although FISH is often the
first line of testing for 1p19q deletions, the technology is
limited and cannot distinguish between full chromo-
somal arm losses as opposed to partial losses that span
the probe sites.
One case (1p19q-03), with diploid copy number along
1p and 19q arms, was tetraploid across the remainder of
the genome (Fig. 1a). Genotyping data from the array in-
dicate that 1p and 19q were co-deleted prior to a doub-
ling of the genome, so that although diploid in number,
the 1p and 19q arms are still deleted in the context of
the entire genome. This is consistent with the FISH find-
ings which compare the 1p or 19q probe to a control
probe found on the opposing chromosome arm.
Overall the 1p19q cohort had a relatively quiet gen-
ome, limited to the 1p and 19q co-deletions. Additional
genomic changes were observed in the 1p19q cohort,
the majority of which were relatively large scale, tending
to encompass entire chromosomes. Genomic gains in-
cluded trisomy 11, 17 & 21, trisomy 22 and one case
that presented a mixed gain of chromosome 7, with 3
copies of 7p and 4 copies of 7q. Genomic losses included
monosomy 14, monosomy 15 & 18, and a second case
of monosomy 18 (Fig. 1b). These changes occurred case
by case and not across the entire cohort, suggesting that
additional genomic changes are not specifically associ-
ated with the 1p19q co-deletions.
EGFR Amplified
The second cohort contained 8 GBM cases positive for
EGFR amplification by FISH. Amplification of EGFR was
confirmed in each case by OncoScan (Figs. 2a and 3a).
Amplifications varied, ranging from 8–61 copies of the
EGFR gene. EGFR copy number (CN) was called by the
analysis software, which is designed to estimate the CN
based on both the log2 ratio, as well as the estimated
tumor content, giving an integer CN call for the tumor
portion of the sample in most cases. In some cases, with
significant tumor heterogeneity, the tumor content can-
not accurately be determined by the software. In these
cases the CN calls are binned and portrayed as an aver-
age CN change across the entire cell population.
We compared the amplification calls made by FISH
with those made by array (Table 1). In addition, 3 sam-
ples were repeated on the array to determine reproduci-
bility. FISH copy numbers were calculated as (signals
counted)/(number of cells). Similar patterns were ob-
served with respect to relative amounts of amplification.
There was some variability in CN estimation—shown by
the repeated arrays. However, the advantage of the CN
call made by the array is that it is an estimation based
on the entire sample, rather than subjectively called after
assessing only regions of amplification. For example,
EGFR-03 contained patches of high amplification amidst
large regions of little or no amplification, within the
tumor. The FISH report reflects a focus on scoring amp-
lified regions while passing over “normal” regions. The
array data, on the other hand, accounts for both, giving
an overall count of EGFR amplification across the
tumor. FISH analysis is open to more subjectivity and in
cases of high copy gains where signals are clustered to-
gether it is often difficult to get an accurate signal count.
After confirming EGFR amplification we analyzed each
case to identify other CNCs found across this cohort.
Recurrent CNCs identified in this group included com-
plex gains across chromosome 7, CDKN2A/B deletions,
loss of chromosome 10 and chromosomal changes of
RB1 affecting 5 of 8 cases (Fig. 2b).
In addition to EGFR amplification we observed a high
degree of complex genomic changes involving chromo-
some 7 (Fig. 3b). All cases within this cohort had gains
encompassing at least 39 % of chromosome 7. Complex
changes included normal diploid segments, long
stretches of single or double copy gains, and isolated re-
gions of amplification not limited to EGFR. It is unclear
whether EGFR amplification is a result of overall
destabilization of the entire chromosome 7, or rather the
initiating cause of it.
Seven cases (88 %) contained homozygous deletions of
CDKN2A/B (Fig. 3c), which is commonly associated
with EGFR amplification in GBM [6, 7]. The last case
(EGFR-07) had a normal diploid count along the 9p
arm, including CDNK2A/B. The remainder of chromo-
some 9 presented a mosaic gain, indicating a relative loss
of 9p (CDNK2A/B), although not to the same extent as
the other cases. EGFR-07 was one of 2 cases that also
contained a complete deletion of the RB1 gene locus.
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Fig. 1 1p19q co-deletion cohort. a Highlights the 1p and 19q co-deletions (deletions marked by indicated region). Case 1p19q-03 had two copies
of 1p and 19q, but was tetraploid throughout the remainder of the genome (blue arrow). b Highlights whole chromosomal changes observed in
this cohort including gains (blue arrows) and deletions (red arrows)
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Fig. 2 Copy number changes observed in GBMs. a A representative sample of EGFR amplification that was confirmed by array in each case (blue
circle). b Additional CNCs observed across the GBM cohort
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Disruption of the Rb pathway is a primary component of
glioma development and can occur through loss of RB1
or CDKN2A/B expression or through amplification of
CDK4 [8, 9, 7]. It is possible that, in this case, deletion
of the RB1 gene precluded the need for CDKN2A/B de-
letion. In addition to CDNK2A/B, the methylthioadeno-
sine phosphorylase (MTAP) gene also falls within the
deleted region, although in EGFR-06 only a hemizygous
loss is observed at the MTAP position as compared to a
very focal homozygous deletion of the CDNK2A/B
genes. Although MTAP has not been extensively charac-
terized, it is commonly deleted in a number of cancers
and there is some evidence that is has tumor suppressive
properties [10–12].
The third recurrent CNC observed across this cohort
was a chromosome 10 deletion (Fig. 3d), observed in all
eight cases (100 %). One case, EGFR-04, presented copy-
neutral LOH, apparently due to a hemizygous loss of
chromosome 10 followed by genome duplication. Dele-
tion of 10q is commonly reported in GBM [13–16], and
may be a mechanism for the inactivation of the tumor
suppressor phosphatase and tensin homolog (PTEN),
which has been associated with GBM [17]. LOH result-
ing from 10q deletion may result in haploinsufficient ex-
pression, or exposure of inactivating PTEN mutations
within the retained allele. However, such a large scale
loss may indicate that additional tumor suppressor genes
across chromosome 10 may also play a role in retaining
cell-cycle equilibrium. Two putative tumor suppressor
genes potentially impacted by chromosome 10 LOH are
ANXA7 and PFKFB3. ANXA7 acts as a positive regulator
of EGFR, and haploinsufficiency of ANXA7 reportedly
Table 1 CN comparison of EGFR by array and FISH
Sample MIP array FISH
EGFR CN Repeat EGFR CN
EGFR-01 37 >20





EGFR-09 34 27 >16.0
EGFR-10 22 18 16.95
aThe tumor content could not be determined, likely due to the presence of
more than 2 cell populations with differing degrees of CNCs. The CN reported
here is therefore an average of the EGFR CN across the entire tissue biopsy
Fig. 3 Additional copy number changes observed in the GBM cohort. a Whole genome overview of the glioblastoma cohort includes
b Chromosome 7 complexity, c CDKN2A/B deletions and d Chromosome 10 deletions
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results in stabilized EGFR protein [18]. Fleischer and col-
leagues showed that LOH of the PFKFB3 gene results in
the reduction of UB12K4 expression, a growth-inhibiting
splice variant of PFKFB3. They concluded that this shift in
UB12K4 expression tends toward more aggressive tumor
growth [19].
The final recurrent CNC observed in this cohort was a
deletion overlapping the RB1 gene in 4 of 8 (50 %) cases.
RB1 gene inactivation has been identified in numerous
cancers [20] either through inactivating mutations or
RB1 deletions (reviewed in [7]). Two cases (EGFR-02 &
EGFR-06) contained partial deletions of RB1, whereas
EGFR-07 & EGFR-10 had deletions spanning the entire
gene locus. As mentioned above, EGFR-07 was the only
case in which the CDKN2A/B locus was not homozy-
gously deleted, which may be in part a result of the RB1
deletion—causing a prior disruption in the Rb pathway
which is often accomplished by the loss of the
CDKN2A/B gene locus. CDKN2A expression has thera-
peutic implications, which in turn may be blocked by
the loss of RB1. For example, deletion of CDKN2A is a
marker of increased sensitivity to the CDK4/6 inhibitor
PD0332991 in melanoma. However, RB1 deletion leads
to PD0332991 resistance, counteracting the CDKN2A-
imbued sensitivity [21]. Testing in GBM cell lines and
GBM xenografts have shown similar results, indicating
that PD0332991 could be effective in treating gliomas,
which typically have CDKN2A/B deletions. Similarly,
PD0332991 resistance was exhibited by cell lines with
RB1 deletion, and also by cell lines lacking the expres-
sion of functional Rb1 protein [22].
Conclusions
Microarray enables us to gain a broader picture of the
CNCs occurring in glioma cases. Gliomas with 1p19q
co-deletion have a relatively quiet genome, apart from
the obvious co-deletion. Additional CNCs are observed
in isolated cases, but appear to occur primarily as larger
aberrations—such as complete loss or gain of entire
chromosomes. On the other hand, EGFR amplified cases
tend to be more complex and have specific abnormal-
ities associated with the EGFR amplification. Further-
more, 1p19q co-deletions and EGFR amplification
associated CNCs appear to be mutually exclusive.
Methods
The samples used in this study were de-identified and
the study was conducted under the University of Utah
Institutional Review Board protocol 7275. Seventeen
cases were selected retrospectively from confirmed gli-
oma diagnoses based on positive FISH results for either
1p19q co-deletions (n = 9) or EGFR amplification (n = 8).
All 17 cases were processed on the OncoScan array de-
signed for copy number analysis of FFPE samples.
Briefly, the OncoScan platform uses MIP probes—linear
probes containing 2 genomic homology regions sepa-
rated by a linker DNA. The probe forms an inverted
loop and binds the gDNA with the homology regions
next to each other flanking a SNP. A dinucleotide com-
plementary to the SNP is incorporated into the probe
resulting in circularization of the MIP probe, then the
gDNA template and unutilized probe are removed via
exonuclease degradation of linear DNA. The probe is
cleaved between universal primer sequences encoded in
the linker region of DNA, which allows for subsequent
amplification of the probe. In the context of the OncoS-
can array, the linker region also encodes a unique mo-
lecular tag corresponding to the genomic region
encoded in the probe. This unique tag is then separated
from the probe and used to interrogate the array.
The raw data was processed using OncoScan® Console
(Affymetrix, Santa Clara, CA) and all cases were analyzed
with Nexus Express software (BioDiscovery, Hawthorne,
CA) to assess CNCs across the genome and identify con-
sistent patterns across each class of gliomas. All calls
made by the software were manually reviewed for probe
performance.
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